[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG10202113337YA - Aggrecan binding immunoglobulins - Google Patents

Aggrecan binding immunoglobulins

Info

Publication number
SG10202113337YA
SG10202113337YA SG10202113337YA SG10202113337YA SG10202113337YA SG 10202113337Y A SG10202113337Y A SG 10202113337YA SG 10202113337Y A SG10202113337Y A SG 10202113337YA SG 10202113337Y A SG10202113337Y A SG 10202113337YA SG 10202113337Y A SG10202113337Y A SG 10202113337YA
Authority
SG
Singapore
Prior art keywords
binding immunoglobulins
aggrecan binding
aggrecan
immunoglobulins
binding
Prior art date
Application number
SG10202113337YA
Inventor
Soren Steffensen
Gerald Beste
Guy Hermans
Hans Gühring
Christoph Ladel
Lars Toleikis
Original Assignee
Ablynx Nv
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv, Merck Patent Gmbh filed Critical Ablynx Nv
Publication of SG10202113337YA publication Critical patent/SG10202113337YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10202113337YA 2017-06-02 2018-06-04 Aggrecan binding immunoglobulins SG10202113337YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762514180P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
SG10202113337YA true SG10202113337YA (en) 2021-12-30

Family

ID=62620830

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202113337YA SG10202113337YA (en) 2017-06-02 2018-06-04 Aggrecan binding immunoglobulins

Country Status (15)

Country Link
US (2) US11603401B2 (en)
EP (1) EP3630818A1 (en)
JP (2) JP7320457B2 (en)
KR (1) KR20200013247A (en)
CN (2) CN118085076A (en)
AR (1) AR112069A1 (en)
AU (2) AU2018277310B2 (en)
BR (1) BR112019025392A2 (en)
CA (1) CA3065630A1 (en)
IL (1) IL270969A (en)
MX (2) MX2019014504A (en)
NZ (1) NZ759601A (en)
SG (1) SG10202113337YA (en)
TW (2) TWI811220B (en)
WO (1) WO2018220225A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2723769T4 (en) 2011-06-23 2022-09-05 Ablynx Nv TECHNIQUES TO PREDICT, DETECT, AND REDUCE UNSPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING VARIABLE IMMUNE GLOBULIN SINGLE DOMAINS
TWI797097B (en) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 Polypeptides comprising an antigen-binding domain and a transport moiety
KR102533814B1 (en) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 Ligand-binding molecules capable of tunable ligand-binding activity
AU2018377783A1 (en) 2017-11-28 2020-06-11 Chugai Seiyaku Kabushiki Kaisha Polypeptide including antigen-binding domain and carrying section
EP3768720A4 (en) 2018-03-20 2022-01-05 Wuxi Biologics Ireland Limited Novel anti-lag-3 antibody polypeptide
WO2019230867A1 (en) * 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising aggrecan binding domain and carrying moiety
GB201918279D0 (en) * 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2023086441A1 (en) * 2021-11-12 2023-05-19 Regents Of The University Of Minnesota Compositions and methods for transcriptional activation
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
KR0184860B1 (en) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 Single domain ligands receptors comprising said ligands methods for their production and use of said ligands
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (en) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Use of stabilized protein or peptide conjugates for the preparation of a drug
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE452975T1 (en) 1992-08-21 2010-01-15 Univ Bruxelles IMMUNOGLOBULINS WITHOUT LIGHT CHAINS
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
WO1994029457A2 (en) 1993-06-09 1994-12-22 Unilever N.V. Process for producing fusion proteins comprising scfv fragments by a transformed mould
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0937140T3 (en) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antibody molecules that interact specifically with the active site or cleavage of a target molecule
EP1027073A2 (en) 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
DK1027439T3 (en) 1997-10-27 2010-05-10 Bac Ip Bv Multivalent antigen-binding proteins
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
ID26964A (en) 1998-02-19 2001-02-22 Xcyte Therapies Inc COMPOSITION AND METHODS FOR SETTING UP LIMFOSIT ACTIVITIES
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
EP1141711A1 (en) 1999-01-05 2001-10-10 Unilever Plc Binding of antibody fragments to solid supports
ATE276359T1 (en) 1999-01-19 2004-10-15 Unilever Nv METHOD FOR PRODUCING ANTIBODY FRAGMENTS
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
CA2370351A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
MXPA01013175A (en) 1999-06-18 2002-06-04 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1.
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (en) 1999-11-18 2001-05-23 Bayer Ag New invertebrate gamma-aminobutyric acid receptor proteins, useful in screening for potential insecticides, for plant protection or medicine, also related nucleic acid
ATE342922T1 (en) 1999-11-29 2006-11-15 Unilever Nv IMMOBILIZATION OF PROTEINS USING A POLYPEPTIDE SEGMENT
PT1233987E (en) 1999-11-29 2009-12-28 Bac Ip B V Immobilized single domain antigen-binding molecules
PT1240337E (en) 1999-12-24 2007-01-31 Genentech Inc Methods and compositions for prolonging elimination half-times of bioactive compounds
DE60138333D1 (en) 2000-03-14 2009-05-28 Unilever Nv Variable heavy chain domains of an antibody to human nutritional lipases and their uses
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
DK1399484T3 (en) 2001-06-28 2010-11-08 Domantis Ltd Double-specific ligand and its use
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd Method of constructing camel antibody library
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
WO2003050531A2 (en) 2001-12-11 2003-06-19 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003054016A2 (en) 2001-12-21 2003-07-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
BRPI0406694B8 (en) 2003-01-10 2021-05-25 Ablynx Nv therapeutic polypeptides, their homologues, their fragments, which are used in the modulations of platelet aggregation
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
DK1639011T3 (en) 2003-06-30 2009-02-16 Domantis Ltd Pegylated Single-Domain Antibodies (dAb)
EP1656128A4 (en) 2003-08-12 2007-02-28 William M Yarbrough Treatment for acne vulgaris and method of use
CN101443043A (en) * 2003-10-08 2009-05-27 杜门蒂斯有限公司 Antibody compositions and methods
DK1687338T3 (en) 2003-11-07 2011-02-07 Ablynx Nv Camelidae single-domain antibodies VHH targeting epidermal growth factor receptor and uses thereof
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
BRPI0518151A2 (en) 2004-10-13 2009-06-16 Ablynx Nv polypeptides against amyloid-beta, nucleic acid encoding such polypeptide, composition comprising such polypeptide, method for producing a polypeptide and use thereof
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
MX363423B (en) 2005-05-18 2019-03-22 Ablynx Nv Improved nanobodies against tumor necrosis factor-alpha.
PT3415535T (en) 2005-05-20 2021-02-02 Ablynx Nv Improved nanobodies tm for the treatment of aggregation-mediated disorders
GB0521392D0 (en) * 2005-10-20 2005-11-30 Nordic Bioscience As Detection or quantification of aggrecan and its fragments
JP2009512844A (en) * 2005-10-20 2009-03-26 ノルディック・バイオサイエンス・ダイアグノスティクス・アクティーゼルスカブ Detection or quantification of aggrecan and its fragments
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CN101663319A (en) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 Be used for the treatment of at the aminoacid sequence of vascular endothelial growth factor and the polypeptide that comprises it and be characterised in that excessive and/or pathologic vessels takes place or the illness and the disease of neovascularization
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
LT3290052T (en) 2008-11-07 2020-02-25 Galaxy Biotech, Llc Monoclonal antibodies to fibroblast growth factor receptor 2
JP5647222B2 (en) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Improved amino acid sequence directed against IL-6R for the treatment of IL-6R related diseases and disorders and polypeptides comprising the same
DK2723769T4 (en) 2011-06-23 2022-09-05 Ablynx Nv TECHNIQUES TO PREDICT, DETECT, AND REDUCE UNSPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING VARIABLE IMMUNE GLOBULIN SINGLE DOMAINS
PT3057992T (en) * 2013-10-15 2024-07-10 Univ Keio Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases

Also Published As

Publication number Publication date
JP2023153140A (en) 2023-10-17
CN110997716A (en) 2020-04-10
US20200140532A1 (en) 2020-05-07
IL270969A (en) 2020-01-30
CN110997716B (en) 2024-03-15
AU2018277310B2 (en) 2024-07-11
KR20200013247A (en) 2020-02-06
MX2024003743A (en) 2024-04-12
CN118085076A (en) 2024-05-28
BR112019025392A2 (en) 2020-07-07
AU2018277310A1 (en) 2019-12-12
JP7320457B2 (en) 2023-08-03
MX2019014504A (en) 2020-07-20
US11603401B2 (en) 2023-03-14
RU2019143589A3 (en) 2021-08-16
US20210115117A9 (en) 2021-04-22
US20230312694A1 (en) 2023-10-05
AU2024223986A1 (en) 2024-10-24
TW201902930A (en) 2019-01-16
NZ759601A (en) 2023-06-30
JP2020522515A (en) 2020-07-30
US20220089703A9 (en) 2022-03-24
EP3630818A1 (en) 2020-04-08
TWI811220B (en) 2023-08-11
WO2018220225A1 (en) 2018-12-06
RU2019143589A (en) 2021-07-09
CA3065630A1 (en) 2018-12-06
TW202413408A (en) 2024-04-01
AR112069A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
IL272643A (en) Binding agents
IL270969A (en) Aggrecan binding immunoglobulins
GB2560203B (en) Smartcard
IL273493A (en) Modified car-t
IL268288A (en) Binding agents
GB2570618B (en) Components
IL270955A (en) Mmp13 binding immunoglobulins
GB201820521D0 (en) n
IL270908A (en) Adamts binding immunoglobulins
GB2562533B (en) Components
GB201701986D0 (en) n
PT3456736T (en) Antibody variants
ZA202001830B (en) Antibody variants
GB201813378D0 (en) n
IL272951A (en) Antibody variants
IL269477A (en) Il-1r-i binding polypeptide
GB201713298D0 (en) Binding agents
GB201713296D0 (en) Binding agents
GB201715149D0 (en) IL-ß binding antibody
GB201701351D0 (en) Binding agents
GB201722104D0 (en) Books etc
GB201711395D0 (en) #50plus
GB201716492D0 (en) Disclosure
GB201715938D0 (en) Disclosure
GB201715756D0 (en) Disclosure